#news #biotech ASCO: Alpine reports 61% ‘clinical benefit’ in early trial of CD28-targeted immuno-oncology drug

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ASCO: Alpine reports 61% ‘clinical benefit’ in early trial of CD28-targeted immuno-oncology drug .ASCO: Alpine reports 61% ‘clinical benefit’ in early trial of CD28-targeted immuno-oncology drug
arlene.weintraub
Mon, 06/07/2021 – 09:46

from FierceBiotech: Biotech https://ift.tt/3wXUHVy